1
|
FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge. NPJ Vaccines 2018; 3:16. [PMID: 29736270 PMCID: PMC5928050 DOI: 10.1038/s41541-018-0051-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Revised: 03/16/2018] [Accepted: 03/21/2018] [Indexed: 11/09/2022] Open
Abstract
Feline immunodeficiency virus (FIV) is the feline analogue to human immunodeficiency virus (HIV) and utilizes parallel modes of receptor-mediated entry. The FIV surface glycoprotein (SU) is an important target for induction of neutralizing antibodies, and autoantibodies to the FIV binding receptor (CD134) block infection ex vivo; thus highlighting the potential for immunotherapies which utilize anti-receptor antibodies to block viral infection. To determine whether vaccination with CD134-SU complexes could induce protection against FIV infection, cats (n = 5 per group) were immunized with soluble CD134, recombinant FIV-SU protein, and/or CD134+SU complexes. Two trials were performed with different antigen combinations and vaccination schedules. In vivo generation of anti-CD134 and anti-SU IgG antibodies was measured, and in vitro neutralization assays were conducted. Immunization induced production of anti-CD134 and anti-SU antibodies that significantly inhibited FIV infection in vitro. However, no vaccine combination protected cats from FIV infection, and neat serum from vaccinated cats enhanced FIV growth in vitro. CD134+SU vaccinated cats exhibited increased CD4:CD8 ratio immediately prior to challenge, and antibodies were much more efficiently generated against vaccine by-products versus target antigens. Results suggest vaccination against viral and cryptic receptor epitopes yields neutralizing antibodies that synergistically inhibit FIV infection in vitro. Factors contributing to vaccine failure may include: (1) Heat-labile serum factors that enhance viral replication, (2) changes in circulating target cell populations induced by vaccination, and (3) weak immunogenicity of neutralizing epitopes compared to off-target vaccine components. Results reinforce the need to monitor vaccine preparation components and avoid non-specific immune stimulation during vaccination. A vaccine candidate for feline immunodeficiency virus elicits strong immunological reaction in vitro, but no protection to live cats. The feline analog to human immunodeficiency virus, FIV shares a similar infection paradigm and has only one partially effective vaccine. A US team, led by Colorado State University’s Susan VandeWoude, immunized cats using a complex of an FIV surface protein and a feline cell-surface protein known to facilitate FIV’s entry into immune cells. Tissue culture assays yielded promising results; however, this did not translate to live-animal protection. The researchers highlighted multiple factors that could explain the lack of success, including circulatory pro-infection factors, and immune responses generated against vaccine by-products rather than intended targets. While the vaccine candidate failed, the research provides invaluable guidance for future efforts into FIV vaccination with implications for HIV vaccine trials.
Collapse
|
2
|
Applications of the FIV Model to Study HIV Pathogenesis. Viruses 2018; 10:v10040206. [PMID: 29677122 PMCID: PMC5923500 DOI: 10.3390/v10040206] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2018] [Revised: 04/17/2018] [Accepted: 04/17/2018] [Indexed: 12/15/2022] Open
Abstract
Feline immunodeficiency virus (FIV) is a naturally-occurring retrovirus that infects domestic and non-domestic feline species, producing progressive immune depletion that results in an acquired immunodeficiency syndrome (AIDS). Much has been learned about FIV since it was first described in 1987, particularly in regard to its application as a model to study the closely related lentivirus, human immunodeficiency virus (HIV). In particular, FIV and HIV share remarkable structure and sequence organization, utilize parallel modes of receptor-mediated entry, and result in a similar spectrum of immunodeficiency-related diseases due to analogous modes of immune dysfunction. This review summarizes current knowledge of FIV infection kinetics and the mechanisms of immune dysfunction in relation to opportunistic disease, specifically in regard to studying HIV pathogenesis. Furthermore, we present data that highlight changes in the oral microbiota and oral immune system during FIV infection, and outline the potential for the feline model of oral AIDS manifestations to elucidate pathogenic mechanisms of HIV-induced oral disease. Finally, we discuss advances in molecular biology, vaccine development, neurologic dysfunction, and the ability to apply pharmacologic interventions and sophisticated imaging technologies to study experimental and naturally occurring FIV, which provide an excellent, but often overlooked, resource for advancing therapies and the management of HIV/AIDS.
Collapse
|
3
|
Human serum protein enhances HIV-1 replication and up-regulates the transcription factor AP-1. Proc Natl Acad Sci U S A 2012; 109:17639-44. [PMID: 23047699 DOI: 10.1073/pnas.1206893109] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
In vitro studies on HIV (HIV-1) replication and neutralization are usually performed in human cell cultures supplemented with FBS instead of human serum (HS). Here we show that in contrast to FBS, addition of increasing amounts of human serum from noninfected donors to the cell culture directly correlates with an increase in HIV-1 replication in vitro. This effect is independent of cell line, virus strain, or batch of pooled human serum used. We found that human serum affects viral transcription in a dose-dependent manner by activating the activator protein-1 (AP-1) member proteins c-FOS, JunD, and JunB in TZM-bl cells. Analysis of the human serum component responsible for this effect indicates that it is a protein having a molecular mass between 250 and 300 kDa. This serum protein, HIV-1 enhancing serum protein (HESP), might promote viral transcription in vivo and consequently play a role in disease progression.
Collapse
|
4
|
Huisman W, Martina BEE, Rimmelzwaan GF, Gruters RA, Osterhaus ADME. Vaccine-induced enhancement of viral infections. Vaccine 2008; 27:505-12. [PMID: 19022319 PMCID: PMC7131326 DOI: 10.1016/j.vaccine.2008.10.087] [Citation(s) in RCA: 136] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2008] [Revised: 10/29/2008] [Accepted: 10/29/2008] [Indexed: 12/19/2022]
Abstract
Examples of vaccine-induced enhancement of susceptibility to virus infection or of aberrant viral pathogenesis have been documented for infections by members of different virus families. Several mechanisms, many of which still are poorly understood, are at the basis of this phenomenon. Vaccine development for lentivirus infections in general, and for HIV/AIDS in particular, has been little successful. Certain experimental lentiviral vaccines even proved to be counterproductive: they rendered vaccinated subjects more susceptible to infection rather than protecting them. For vaccine-induced enhanced susceptibility to infection with certain viruses like feline coronavirus, Dengue virus, and feline immunodeficiency virus, it has been shown that antibody-dependent enhancement (ADE) plays an important role. Other mechanisms may, either in the absence of or in combination with ADE, be involved. Consequently, vaccine-induced enhancement has been a major stumble block in the development of certain flavi-, corona-, paramyxo-, and lentivirus vaccines. Also recent failures in the development of a vaccine against HIV may at least in part be attributed to induction of enhanced susceptibility to infection. There may well be a delicate balance between the induction of protective immunity on the one hand and the induction of enhanced susceptibility on the other. The present paper reviews the currently known mechanisms of vaccine-induced enhancement of susceptibility to virus infection or of aberrant viral pathogenesis.
Collapse
Affiliation(s)
- W Huisman
- Erasmus MC, Institute of Virology, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands
| | | | | | | | | |
Collapse
|
5
|
Ramnarine EJ, Devico AL, Vigil-Cruz SC. Analogues of N-terminal truncated synthetic peptide fragments derived from RANTES inhibit HIV-1 infectivity. Bioorg Med Chem Lett 2006; 16:93-5. [PMID: 16236501 DOI: 10.1016/j.bmcl.2005.09.044] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2005] [Revised: 09/13/2005] [Accepted: 09/16/2005] [Indexed: 10/25/2022]
Abstract
A series of synthetic peptide fragments derived from RANTES were designed, synthesized, and evaluated to determine the effect of N-terminal truncation on the ability of the lead compound Ac[Ala(10,11)]RANTES-(1-14)NH(2) to inhibit HIV-1 infectivity. Both the lead compound and the truncated analogue Ac[Ala(10,11)]RANTES-(3-14)NH(2) were able to significantly inhibit HIV-1 infectivity. These results suggest that a small synthetic peptide may be able to mimic RANTES and have the ability to prevent transmission of HIV-1.
Collapse
Affiliation(s)
- Emabelle J Ramnarine
- Department of Pharmaceutical Sciences, University of Connecticut, 69 North Eagleville Road, Storrs, CT 06269, USA
| | | | | |
Collapse
|
6
|
Stewart M, Desport M, Hartaningsih N, Wilcox G. TaqMan real-time reverse transcription-PCR and JDVp26 antigen capture enzyme-linked immunosorbent assay to quantify Jembrana disease virus load during the acute phase of in vivo infection. J Clin Microbiol 2005; 43:5574-80. [PMID: 16272489 PMCID: PMC1287780 DOI: 10.1128/jcm.43.11.5574-5580.2005] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Jembrana disease virus (JDV) is an acutely pathogenic lentivirus that affects Bali cattle in Indonesia. The inability to propagate the virus in vitro has made it difficult to quantitate JDV and determine the kinetics of virus replication during the acute phase of the disease process. We report for the first time two techniques that enable quantification of the virus and the use of these techniques to quantify the virus load during the acute phase of the disease process. A one-step JDV gag [corrected] TaqMan real-time reverse transcription-PCR (RT-PCR) assay was developed for the detection and quantification of JDV RNA in plasma. The limit of detection was 9.8 x 10(2) JDV viral RNA copies over 35 cycles, equivalent to 4.2 x 10(4) JDV genome copies/ml, and a peak virus load of 1.6 x 10(12) during the acute febrile period. An antigen capture enzyme-linked immunosorbent assay (ELISA) was also developed to quantify the levels of JDV capsid (JDVp26) over a linear range of 10 to 200 ng/ml. Viral RNA and JDVp26 levels were correlated in 48 plasma samples obtained from experimentally infected cattle. A significant positive correlation (R = 0.860 and r(2) = 0.740) was observed between the two techniques within the range of their detection limits. The relatively insensitive capture ELISA provides an economical and feasible method for monitoring of virus in the absence of more sensitive techniques.
Collapse
Affiliation(s)
- Meredith Stewart
- School of Veterinary and Biomedical Science, Murdoch University, South St., Murdoch, WA 6150, Australia
| | | | | | | |
Collapse
|
7
|
Ramnarine E, DeVico AL, Vigil-Cruz SC. A synthetic peptide fragment derived from RANTES is a potent inhibitor of HIV-1 infectivity despite a surprising lack of CCR5 receptor affinity. Int J Pept Res Ther 2005. [DOI: 10.1007/s10989-005-3969-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Someya K, Cecilia D, Ami Y, Nakasone T, Matsuo K, Burda S, Yamamoto H, Yoshino N, Kaizu M, Ando S, Okuda K, Zolla-Pazner S, Yamazaki S, Yamamoto N, Honda M. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. J Virol 2005; 79:1452-62. [PMID: 15650171 PMCID: PMC544111 DOI: 10.1128/jvi.79.3.1452-1462.2005] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Although the correlates of vaccine-induced protection against human immunodeficiency virus type 1 (HIV-1) are not fully known, it is presumed that neutralizing antibodies (NAb) play a role in controlling virus infection. In this study, we examined immune responses elicited in rhesus macaques following vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin expressing an HIV-1 Env V3 antigen (rBCG Env V3). We also determined the effect of vaccination on protection against challenge with either a simian-human immunodeficiency virus (SHIV-MN) or a highly pathogenic SHIV strain (SHIV-89.6PD). Immunization with rBCG Env V3 elicited significant levels of NAb for the 24 weeks tested that were predominantly HIV-1 type specific. Sera from the immunized macaques neutralized primary HIV-1 isolates in vitro, including HIV-1BZ167/X4, HIV-1SF2/X4, HIV-1CI2/X4, and, to a lesser extent, HIV-1MNp/X4, all of which contain a V3 sequence homologous to that of rBCG Env V3. In contrast, neutralization was not observed against HIV-1SF33/X4, which has a heterologous V3 sequence, nor was it found against primary HIV-1 R5 isolates from either clade A or B. Furthermore, the viral load in the vaccinated macaques was significantly reduced following low-dose challenge with SHIV-MN, and early plasma viremia was markedly decreased after high-dose SHIV-MN challenge. In contrast, replication of pathogenic SHIV-89.6PD was not affected by vaccination in any of the macaques. Thus, we have shown that immunization with an rBCG Env V3 vaccine elicits a strong, type-specific V3 NAb response in rhesus macaques. While this response was not sufficient to provide protection against a pathogenic SHIV challenge, it was able to significantly reduce the viral load in macaques following challenge with a nonpathogenic SHIV. These observations suggest that rBCG vectors have the potential to deliver an appropriate virus immunogen for desirable immune elicitations.
Collapse
Affiliation(s)
- Kenji Someya
- AIDS Research Center, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo 162-8640, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Huisman W, Schrauwen EJA, Pas SD, Karlas JA, Rimmelzwaan GF, Osterhaus ADME. Antibodies specific for hypervariable regions 3 to 5 of the feline immunodeficiency virus envelope glycoprotein are not solely responsible for vaccine-induced acceleration of challenge infection in cats. J Gen Virol 2004; 85:1833-1841. [PMID: 15218167 DOI: 10.1099/vir.0.79949-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
In a previous vaccination study in cats, the authors reported on accelerated feline immunodeficiency virus (FIV) replication upon challenge in animals vaccinated with a candidate envelope subunit vaccine. Plasma transfer studies as well as antibody profiles in vaccinated cats indicated a causative role for antibodies directed against the hypervariable regions HV3, HV4 and HV5 (HV3-5) of the envelope glycoprotein. The present study was designed to investigate further the contribution of antibodies in envelope vaccine-induced acceleration of FIV infection. To this end, regions HV3-5 of the envelope glycoprotein were deleted from the original vaccine, thus addressing the contributing role of antibodies directed against these hypervariable regions. Interestingly, this approach did not prevent acceleration of challenge infection. Analysis of the antibody responses in the respective groups suggested that removal of HV3-5 redirected the humoral immune response towards other regions of the envelope glycoprotein, indicating that these regions can also induce antibodies that accelerate virus replication.
Collapse
Affiliation(s)
- Willem Huisman
- Erasmus MC, Institute of Virology, PO Box 1738, 3000 DR Rotterdam, The Netherlands
| | - Eefje J A Schrauwen
- Erasmus MC, Institute of Virology, PO Box 1738, 3000 DR Rotterdam, The Netherlands
| | - Suzan D Pas
- Erasmus MC, Institute of Virology, PO Box 1738, 3000 DR Rotterdam, The Netherlands
| | - Jos A Karlas
- Erasmus MC, Institute of Virology, PO Box 1738, 3000 DR Rotterdam, The Netherlands
| | - Guus F Rimmelzwaan
- Erasmus MC, Institute of Virology, PO Box 1738, 3000 DR Rotterdam, The Netherlands
| | | |
Collapse
|
10
|
A synthetic peptide fragment derived from RANTES is a potent inhibitor of HIV-1 infectivity despite a surprising lack of CCR5 receptor affinity. Int J Pept Res Ther 2003. [DOI: 10.1007/bf02442598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Skurnick JH, Palumbo P, DeVico A, Shacklett BL, Valentine FT, Merges M, Kamin-Lewis R, Mestecky J, Denny T, Lewis GK, Lloyd J, Praschunus R, Baker A, Nixon DF, Stranford S, Gallo R, Vermund SH, Louria DB. Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. J Infect Dis 2002; 185:428-38. [PMID: 11865394 PMCID: PMC2743095 DOI: 10.1086/338830] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2001] [Revised: 09/13/2001] [Indexed: 11/03/2022] Open
Abstract
Seventeen women who were persistently uninfected by human immunodeficiency virus type 1 (HIV-1), despite repeated sexual exposure, and 12 of their HIV-positive male partners were studied for antiviral correlates of non-transmission. Thirteen women had > or = 1 immune response in the form of CD8 cell noncytotoxic HIV-1 suppressive activity, proliferative CD4 cell response to HIV antigens, CD8 cell production of macrophage inflammatory protein-1 beta, or ELISPOT assay for HIV-1-specific interferon-gamma secretion. The male HIV-positive partners without AIDS had extremely high CD8 cell counts. All 8 male partners evaluated showed CD8 cell-related cytotoxic HIV suppressive activity. Reduced CD4 cell susceptibility to infection, neutralizing antibody, single-cell cytokine production, and local antibody in the women played no apparent protective role. These observations suggest that the primary protective factor is CD8 cell activity in both the HIV-positive donor and the HIV-negative partner. These findings have substantial implications for vaccine development.
Collapse
Affiliation(s)
- Joan H. Skurnick
- Department of Preventive Medicine and Community Health, New Jersey Medical School, Newark
| | - Paul Palumbo
- Department of Preventive Medicine and Community Health, New Jersey Medical School, Newark
| | - Anthony DeVico
- Institute of Human Virology, University of Maryland, Baltimore
| | - Barbara L. Shacklett
- Aaron Diamond AIDS Research Center, Rockefeller University
- Reprints or correspondence: Dr. Joan H. Skurnick, New Jersey Medical School, Dept. of Preventive Medicine and Community Health, 185 S. Orange Ave., Newark, NJ 07103-2714 ()
| | - Fred T. Valentine
- Department of Medicine, New York University School of Medicine, New York
| | - Michael Merges
- Institute of Human Virology, University of Maryland, Baltimore
| | - Roberta Kamin-Lewis
- Institute of Human Virology, University of Maryland, Baltimore
- Department of Microbiology and Immunology, University of Maryland, Baltimore
| | - Jiri Mestecky
- Department of Microbiology and Medicine, University of Alabama at Birmingham
| | - Thomas Denny
- Department of Preventive Medicine and Community Health, New Jersey Medical School, Newark
| | - George K. Lewis
- Institute of Human Virology, University of Maryland, Baltimore
| | - Joan Lloyd
- Department of Preventive Medicine and Community Health, New Jersey Medical School, Newark
| | | | - Amanda Baker
- Institute of Human Virology, University of Maryland, Baltimore
| | - Douglas F. Nixon
- Aaron Diamond AIDS Research Center, Rockefeller University
- Reprints or correspondence: Dr. Joan H. Skurnick, New Jersey Medical School, Dept. of Preventive Medicine and Community Health, 185 S. Orange Ave., Newark, NJ 07103-2714 ()
| | - Sharon Stranford
- Department of Medicine, University of California, San Francisco
- Reprints or correspondence: Dr. Joan H. Skurnick, New Jersey Medical School, Dept. of Preventive Medicine and Community Health, 185 S. Orange Ave., Newark, NJ 07103-2714 ()
| | - Robert Gallo
- Institute of Human Virology, University of Maryland, Baltimore
| | - Sten H. Vermund
- Division of Geographic Medicine, University of Alabama at Birmingham
| | - Donald B. Louria
- Department of Preventive Medicine and Community Health, New Jersey Medical School, Newark
| |
Collapse
|
12
|
Godard CM, Chermann JC. Experimental conditions that increase the production of HIV-1 by monocyte-derived macrophages: use of collagen matrix. Microbes Infect 1999; 1:765-70. [PMID: 10816081 DOI: 10.1016/s1286-4579(99)80078-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Monocyte-derived macrophages (MDMs) from healthy blood donors were isolated by adherence to tissue culture-treated plasticware. They were cultured in vitro in medium supplemented with human serum and recombinant GM-CSF, then infected with the macrophage-tropic prototype strain HIV-1-PAR. Virus production was quantitated at various times after infection by measuring reverse transcriptase concentration in cell-free tissue culture supernatant fluids, using a sensitive nonradioactive assay. Virus production was significantly increased by culturing MDMs on plasticware previously coated with collagen 1. The increase in virus production was dependent upon collagen 1 concentration, with maximal value being encountered after coating with 1.5 microg/cm2. These results indicate that the sensitivity of peripheral macrophages to HIV-1 infection might be influenced by contact-dependent interactions involving components of the extracellular matrix that take place during the process of monocyte extravasation and migration.
Collapse
Affiliation(s)
- C M Godard
- Inserm Unité 322, Parc Scientifique et Technologique de Luminy, Marseille, France
| | | |
Collapse
|
13
|
Raabe ML, Issel CJ, Montelaro RC. In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus. Virology 1999; 259:416-27. [PMID: 10388665 DOI: 10.1006/viro.1999.9772] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We have previously demonstrated a high propensity for enhancement of virus replication and disease resulting from experimental immunization of ponies with a baculovirus recombinant envelope (rgp90) vaccine from equine infectious anemia virus (EIAV). The current studies were undertaken to examine the correlation between the observed in vivo vaccine enhancement and in vitro assays for antibody-dependent enhancement (ADE) of EIAV replication. Toward this goal an optimized EIAV in vitro enhancement assay was developed using primary equine macrophage cells and used to evaluate the enhancement properties of immune serum taken from rgp90 immunized ponies that displayed various levels of vaccine enhancement after experimental challenge with EIAV. For comparison, we analyzed in parallel immune serum samples from a group of ponies immunized with a viral envelope subunit vaccine (LL-gp) that produced sterile protection from EIAV challenge. The results of these assays demonstrated that the rgp90 immune serum had a greater propensity for in vitro enhancement of EIAV replication than serum from the protected LL-gp immunized ponies; in vitro enhancement levels for the rgp90 immune sera averaged about 1.5, with a maximum enhancement value of about 2.0. While distinguishing between immune serum produced by the rgp90 and LL-gp immunizations, the in vitro enhancement assay failed to reliably correlate with the severity of in vivo enhancement observed among the rgp90 vaccine recipients. Vaccinated ponies that experienced moderate to no disease signs displayed levels of in vitro enhancement similar to those of ponies that experienced severe and fatal enhancement of disease after viral challenge. The observed in vitro enhancement was demonstrated to be dependent on serum immunoglobulin, but independent of complement. These studies demonstrate in the EIAV system that in vitro ADE assays appear to be relatively insensitive indicators of the severity of in vivo enhancement and that relatively low levels of in vitro ADE can be associated with severe to fatal enhancement of virus replication and disease in vivo. These observations suggest that relatively low levels of serum ADE observed in other lentivirus systems, including HIV-1, may have more profound effects on in vivo virus replication and disease than previously recognized.
Collapse
Affiliation(s)
- M L Raabe
- Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, 15261, USA
| | | | | |
Collapse
|
14
|
Spouge JL, Layne SP. A practical method for simultaneously determining the effective burst sizes and cycle times of viruses. Proc Natl Acad Sci U S A 1999; 96:7017-22. [PMID: 10359831 PMCID: PMC22041 DOI: 10.1073/pnas.96.12.7017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
We describe combined analytic and experimental methods for determining reproductive statistics from time-series data. Our computational methods derive four fundamental measures from laboratory experiments: (i) average number of viral daughters; (ii) mean viral cycle time; (iii) standard deviation of the viral cycling time; and (iv) viral doubling time. Taken together, these four reproductive statistics characterize "age-specific fertility," a quantity that provides complete information on the reproduction of the average viral particle. In this paper, we emphasize applications relating to HIV and experiments for assessing cellular tropism, viral phenotypes, antiviral drugs, humoral immunity, and cytotoxic cellular immunity. Nevertheless, our method is quite flexible and applicable to the evaluation of drugs against bacterial, fungal, and parasitic infections, antineoplastic agents against cancer cells, and perturbations involving pest and wildlife releases in ecosystems.
Collapse
Affiliation(s)
- J L Spouge
- National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD 20894, USA.
| | | |
Collapse
|
15
|
Tsai WP, Kung HF, Nara PL. The presence and absence of histocompatibility antigens in HIV type 1 produced by autologous blood-derived macrophages and peripheral blood lymphoblasts. AIDS Res Hum Retroviruses 1999; 15:33-41. [PMID: 10024050 DOI: 10.1089/088922299311682] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
Abstract
Acquisition of cellular proteins by HIV-1 virions is known to alter the physiology of the virus in vitro. Reported studies of this aspect have been largely limited to transformed T cell lines. In this study, we investigated the incorporation of major histocompatibility antigens (HLAs) on a primary macrophage-tropic isolate, HIV-1ADA, grown from autologous monocyte-derived macrophages (MDMs) and peripheral blood mononuclear cells (PBMCs). A virus precipitation assay (VPA) demonstrated that HIV-1ADA grown from PBMCs incorporated substantial amounts of HLA class I (alpha chain and beta2m) and DR antigens, comparable with a laboratory strain, HIV-1MN, grown from the same host cells. HIV-1ADA, however, grown from MDMs incorporated significantly lower amounts of HLAI and -II antigens despite the fact that the infected MDMs were found to express significant amounts of HLA antigens. The lack of incorporation of these important immunomodulatory cell surface proteins may be yet another unique characteristic of macrophage-tropic isolates and suggests a possible role in their biology and or immunology.
Collapse
Affiliation(s)
- W P Tsai
- Laboratory of Biochemical Physiology, NCI/FCRDC, Frederick, Maryland 21702, USA.
| | | | | |
Collapse
|
16
|
Del Mauro D, Matteucci D, Giannecchini S, Maggi F, Pistello M, Bendinelli M. Autologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates. J Virol 1998; 72:2199-207. [PMID: 9499077 PMCID: PMC109516 DOI: 10.1128/jvi.72.3.2199-2207.1998] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Feline immunodeficiency virus (FIV) provides a model system with which the significance of neutralizing antibody (NA) in immunosuppressive lentivirus infections may be studied. To date, no detailed analysis of the neutralization properties of primary FIV isolates has been reported. In this study, we have conducted the first comprehensive study of the sensitivity to autologous and heterologous neutralization in a lymphoid cell-based assay of 15 primary FIV isolates and, for comparison, of one tissue culture-adapted strain. Primary isolates in general proved highly NA resistant, although there was considerable individual variation. Variation was also observed in the capacity of immune sera to neutralize heterologous FIV isolates. The ability of sera to neutralize isolates or for isolates to be neutralized by sera did not correlate with epidemiological and genetic relatedness or with the quasispecies complexity of the isolates. From the study of specific-pathogen-free cats experimentally infected with viral isolates associated with NA of different breadths, it appears that the development of FIV vaccines cannot rely on the existence of viral strains inherently capable of inducing especially broad NA responses.
Collapse
Affiliation(s)
- D Del Mauro
- Retrovirus Center and Virology Section, Department of Biomedicine, University of Pisa, Italy
| | | | | | | | | | | |
Collapse
|
17
|
Raabe MR, Issel CJ, Montelaro RC. Equine monocyte-derived macrophage cultures and their applications for infectivity and neutralization studies of equine infectious anemia virus. J Virol Methods 1998; 71:87-104. [PMID: 9628225 DOI: 10.1016/s0166-0934(97)00204-8] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Equine infectious anemia virus (EIAV) has been shown to infect cells of monocyte/macrophage lineage. These primary cells are intrinsically difficult to obtain, to purify and to culture in vitro for extended periods of time. As a result, most in vitro studies concerning this lentivirus make use of primary equine fibroblasts or transformed canine or feline cell lines. We describe methods that yield reproducibly pure cultures of equine blood monocytes from peripheral blood mononuclear cells. The in vitro differentiation of these cells into mature equine macrophage was verified using various cytochemical staining methods. The equine monocyte-derived macrophage (MDM) cultures were found to replicate cell-adapted and field strains of EIAV more efficiently than cultures of fully differentiated equine splenic macrophage. Having established reproducible and fully differentiated cultures of equine macrophage, in vitro assays of virus infectivity and serum neutralization were developed using the in vivo target cell of EIAV. These procedures, while developed for the EIAV system, should be equally useful for in vitro cultures of other macrophage-tropic pathogens of horses.
Collapse
Affiliation(s)
- M R Raabe
- Department of Molecular Genetics and Biochemistry, School of Medicine, University of Pittsburgh, Pennsylvania 15261, USA
| | | | | |
Collapse
|
18
|
De Francesco MA, Caruso A, Fallacara F, Canaris AD, Dima F, Poiesi C, Licenziati S, Corulli M, Martinelli F, Fiorentini S, Turano A. HIV p17 enhances lymphocyte proliferation and HIV-1 replication after binding to a human serum factor. AIDS 1998; 12:245-52. [PMID: 9517986 DOI: 10.1097/00002030-199803000-00001] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE To analyse the role of recombinant HIV-1 protein p17 in the modulation of cell activity. METHODS Peripheral blood mononuclear cells (PBMC) obtained from healthy donors were cultured in the presence or absence of p17 with mitogens such as phytohaemagglutinin or interleukin-2 and their response assayed by cell proliferation. Cross-linking experiments were employed to investigate the presence of a binding between p17 and factor(s) present in human serum. An immunoenzymatic assay for p24 antigen detection was used to analyse the effect of the addition of exogenous p17 to cultures of PBMC infected with HIV-1 in vitro. RESULTS Purified recombinant p17 protein at a concentration of 0.25 microg/ml significantly increased the proliferation of preactivated PBMC obtained from healthy donors. This effect was obtained by binding p17 to factor(s) present in human serum and observed on both CD4+ and CD8+ T cells. Recombinant p17 also induced an increased rate of HIV-1 replication, probably due to enhanced T-cell proliferation. The activity of p17 protein was inhibited by anti-p17 antibodies generated by injecting recombinant p17 in rabbits, but not by human antibodies generated during the natural course of HIV infection. CONCLUSION Characterization of the human factor(s) and identification of the interacting p17 epitope(s) will improve our understanding of the mechanisms used by HIV to efficiently replicate in our organisms.
Collapse
Affiliation(s)
- M A De Francesco
- Institute of Microbiology, Brescia University Medical School, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Nielsen SD, Sørensen AM, Schønning K, Lund O, Nielsen JO, Hansen JE. Complement-mediated enhancement of HIV-1 infection in peripheral blood mononuclear cells. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 1998; 29:447-52. [PMID: 9435030 DOI: 10.3109/00365549709011852] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We investigated if complement-mediated enhancement of HIV infection occurs in peripheral blood mononuclear cells (PBMC). In 7 experiments, we evaluated the effect of human complement on HIVIIIB infection in vitro. We measured HIV antigen production on day 4 and found that pre-incubation of HIV with complement led to enhanced production of antigen with a median enhancement of 2.5-fold (range 1.1-6.8). This complement-mediated increase in antigen production was statistically significant (p < 0.02). Complement-mediated enhancement of HIV infection was also tested in CD4 cells enriched from PBMC, and CD4 cells persistently gave higher levels of infection enhancement than PBMC. Thus, CD4 cells appear to be sufficient for complement-mediated enhancement of HIV infection to occur. In addition, we tested if it was possible to detect complement-mediated enhancement of primary HIV isolates in PBMC. We tested 3 isolates and found only a minor effect on antigen production (median enhancement 1.2-fold, range 0.6-1.5). Furthermore, addition of HIV-specific antibodies in combination with complement resulted in enhanced antigen production in 2/3 sera tested. However, the combination of complement and antibodies resulted in only a minor increase in enhancement of HIV infection compared to that obtained with complement alone. Finally, we found evidence of complement-mediated enhancement of HIV infection in resting PBMC. In conclusion, we demonstrated that complement-mediated enhancement of HIV infection does occur in vitro in PBMC.
Collapse
Affiliation(s)
- S D Nielsen
- Department of Infectious Diseases, Hvidovre Hospital, Denmark
| | | | | | | | | | | |
Collapse
|
20
|
Tsai WP, Rimelzwaan GF, Merges MJ, Wu SC, Conley S, Kung HF, Garrity R, Goudsmit J, Nara PL. Preliminary findings of an in vitro human spleen mononuclear cell culture system for primary isolates of HIV type 1. AIDS Res Hum Retroviruses 1997; 13:967-77. [PMID: 9223413 DOI: 10.1089/aid.1997.13.967] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Acute HIV-1 infection is often manifested with a high level of viremia. The cell types and tissues/organs that contribute to the virus load are thought to be of central and peripheral lymphoreticular origin. The establishment and permissiveness of organ-based cell culture systems from spleen with laboratory strains or primary isolates of HIV-1 have not been reported. We studied unseparated splenic mononuclear cells (SMCs) and adherent cells derived from human spleen and liver in comparison with blood monocyte-derived macrophages (MDMs). Unstimulated, SMCs were highly permissive to primary lymphotropic HIV-1 and dual/macrophage-tropic isolates (which are able to replicate in both MDMs and PBMCs). Furthermore, SMCs were found to replicate virus to high titer in a rapid log-phase manner and exhibited a prolonged stationary phase of virus production, unlike PBMCs, which required conventional activation with mitogens and exhibited a much shorter period of virus production. Interestingly, the SMCs maintained themselves as a mixed phenotype of nested lymphocytes with complex and well-differentiated macrophage(s) for extended periods of time. In addition, splenic macrophages readily purified by adherence were highly permissive to a dual/macrophage-tropic primary isolate, HIV-1ADA, intermediate with two laboratory strains, HIVR-1RF and HIV-lHXB3, and least permissive to the lymphotropic primary isolate HIV-1Mr452 and two other laboratory strains, HIV-1CC and HIV-1MN. The replication of HIV-1ADA as measured by extracellular p24 was sustained for up to 7 weeks and similar to the replication patterns observed with adherent hepatic macrophages and blood-derived MDMs. This study demonstrates that exogenous stimulation is not required for infection of these cells; either adherence-isolated and/or mixed lymphoid populations can be studied together, and viable stocks can be readily prepared and cryopreserved. In addition, these cells could be used for isolating new and/or other variants of HIV-1. Thus, the use of the SMC primary in vitro cell culture system for future studies involving HIV-1 is warranted.
Collapse
Affiliation(s)
- W P Tsai
- Laboratory of Biochemical Physiology, Division of Basic Science, NCI-FCRDC, Frederick, Maryland 21702, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
Despite intensive experimental work on HIV-1, very little theoretical work has focused on HIV-1 spread in tissue culture. This article uses two systems of ordinary differential equations to model two modes of viral spread, cell-free virus and cell-to-cell contact. The two models produce remarkably similar qualitative results. Simulations using realistic parameter regimes showed that starting with a small fraction of cells infected, both cell-free viral spread and direct cell-to-cell transmission give an initial exponential phase of viral growth, followed by either a crash or a gradual decline, extinguishing the culture. Under some conditions, an oscillatory phase may precede the extinction. Some previous models of in vivo HIV-1 infection oscillate, but only in unrealistic parameter regimes. Experimental tissue infections sometimes display several sequential cycles of oscillation, however, so our models can at least mimic them qualitatively. Significantly, the models show that infective oscillations can be explained by infection dynamics; biological heterogeneity is not required. The models also display proportionality between infected cells and cell-free virus, which is reassuringly consistent with assumptions about the equivalence of several measures of viral load, except that the proportionality requires a relatively constant total cell concentration. Tissue culture parameter values can be determined from accurate, controlled experiments. Therefore, if verified, our models should make interpreting experimental data and extrapolating it to in vivo conditions sharper and more reliable.
Collapse
Affiliation(s)
- J I Spouge
- National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, USA
| | | | | |
Collapse
|
22
|
Wu SC, Spouge JL, Merges MJ, Conley SR, Nara PL. A cytopathic infectivity assay of human immunodeficiency virus type 1 in human primary macrophages. J Virol Methods 1996; 59:45-55. [PMID: 8793829 DOI: 10.1016/0166-0934(96)02005-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
In addition to CD4+ T lymphocytes, cells of monocyte/macrophage lineage are a major target for human immunodeficiency virus type 1 (HIV-1) infection. In vitro studies of HIV-1 infection in human monocyte-derived macrophages can be undertaken by a reproducible cell-based assay. A macrophage-based infectivity assay was developed based on the semi-quantitative scoring of HIV-1 induced cytopathology in monolayer macrophage cultures. The assay exhibited dilution-dependent linearity with all three primary macrophage-tropic isolates tested. The end-point infectivity titers determined by this assay correlated with the results obtained by detecting viral p24 antigen in the culture supernatant. The applications of the assay in both neutralization and anti-viral protocols yielded identical results with the more time-consuming and costly p24 formats. Since the assay offers a simple and low-cost method of measuring HIV-1 infectivity in human primary macrophages, it can be used quite easily for large-scale screening or evaluation of candidate vaccines and anti-viral agents.
Collapse
Affiliation(s)
- S C Wu
- National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD 20894, USA
| | | | | | | | | |
Collapse
|
23
|
Abstract
Human immunodeficiency virus (HIV-1) was inactivated by either cupric or ferric ions when the virus was free in solution and also 3 hr after cell infection. Fifty percent inactivation of cell-free HIV was achieved with Cu(II) at a concentration between 0.16 and 1.6 mM, or by 1.8 to 18 mM Fe(III). Thus, the dose to inactivate 50% of infectious HIV (D50) by Cu(II) or Fe(III) is higher than that reported for glutaraldehyde (0.1 mM); between the D50 reported for sodium hypochlorite (1.3 mM) and sodium hydroxide (11.5 mM), and significantly lower than that required for HIV inactivation by ethanol (360 mM). Treatment of infected cells for 30 min at 20 degrees C with 6 mM Cu(II) or Fe(III) completely inhibited the formation of syncytia and the synthesis of virus-specific p24 antigen in HIV-infected cells, while still preserving cell viability. The virucidal properties of cupric and ferric ions could be exploited for the development of novel virucidal formulations efficient against HIV.
Collapse
Affiliation(s)
- J L Sagripanti
- Molecular Biology Branch (HFZ-113), Center for Devices and Radiological Health, Food and Drug Administration, Rockville, Maryland 20857, USA
| | | |
Collapse
|
24
|
Auewarakul P, Louisirirotchanakul S, Sutthent R, Taechowisan T, Kanoksinsombat C, Wasi C. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand. Viral Immunol 1996; 9:175-85. [PMID: 8890476 DOI: 10.1089/vim.1996.9.175] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Twenty-seven HIV-1 isolates were obtained from 51 asymptomatic HIV-1-infected pregnant women or intravenous drug users (IDUs) in Bangkok. Using heteroduplex mobility assay (HMA), it was found that the majority of the HIV-1 isolates (9 out of 11) from pregnant women belonged to genetic subtype E, whereas most of the subtype B HIV-1 isolates (15 out of 16) were isolated from IDUs. The HIV-1 isolates were tested for their susceptibility to neutralization or antibody-dependent enhancement with homologous and heterologous plasma of the two different genetic subtypes, B and E. Overall, HIV-1 neutralizing activity could be found in 37.3% of virus/plasma pairs for both subtypes B and E. No significant correlation could be identified between the two genetic subtypes (B and E) and their susceptibility to neutralization. Subtype B plasma demonstrated frequent cross-neutralization of subtype E viruses in 38.5% of virus/plasma pairs, whereas cross-neutralization activity of subtype E specific plasma samples was more limited and could cross-neutralize subtype B viruses only in 15.8% of cases. Some of the viral strains independently of their genetic subtypes were more susceptible to neutralization by plasma specific for both subtype E or subtype B, suggesting that this phenomenon is related to the proper biological properties of a viral strain. Antibody-dependent enhancement of HIV-1 strains could be detected in 12/83 (14.5%) virus-plasma pairs irrespective of genetic subtypes. Similar to neutralization results, the HIV-1 enhancing activity of plasma was mostly isolate-specific. The HIV isolates that were susceptible to neutralization were not enhanced by any plasma. On the other hand, the HIV isolates that were enhanced by plasma were resistant to neutralization in most cases. Such a dissociation between susceptibility to neutralization or enhancement may be indicative of the existence of discrete epitopes determining the two distinct viral properties.
Collapse
Affiliation(s)
- P Auewarakul
- WHO Collaborating Centre on AIDS, Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | | | | | | | | | | |
Collapse
|
25
|
Kostrikis LG, Cao Y, Ngai H, Moore JP, Ho DD. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 1996; 70:445-58. [PMID: 8523557 PMCID: PMC189833 DOI: 10.1128/jvi.70.1.445-458.1996] [Citation(s) in RCA: 133] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Human immunodeficiency virus type 1 (HIV-1) M group strains have been assigned to date to nine distinct genetic subtypes, designated A through I, according to phylogenetic analyses of nucleotide sequences of their env or gag genes. Whether there is any relationship between phylogenetic subtypes and the neutralization serotypes is not clear, yet defining the nature of any such relationship by mathematical means would be of major importance for the development of globally effective HIV-1 vaccines. We have therefore developed a quantitative method to analyze serum neutralization of HIV-1 isolates and to identify HIV-1 neutralization serotypes. This method involves calculations of the neutralization index, N(i), a newly defined parameter derived from plots generated from in vitro neutralization assays, calculations of pairwise serum-virus vector distances, and cluster analyses. We have applied this approach to analyze three independent neutralization matrices involving primary HIV-1 strains and sera from genetic subtypes A, B, C, D, E, F, and I. Detailed serum and HIV-1 isolate cluster analyses have shown that in general, the identified neutralization serotypes do not directly correlate with HIV-1 genetic subtypes. These results suggest that neutralization serotypes do not during natural HIV-1 infection are not governed by antibodies directed against simple epitopes within gp120 monomers. A significant proportion (28%) of 1,213 combinations of sera and HIV-1 isolates caused serum-dependent infectivity enhancement [negative N(i) values] rather than neutralization. We also noted that negative N(i) values tended to correlate better with certain HIV-1 isolates rather than with HIV-1-positive sera. Syncytium-inducing variants of HIV-1 were slightly more likely than non-syncytium-inducing variants to undergo serum-dependent infectivity enhancement, although the latter variants could clearly be susceptible to enhancement.
Collapse
Affiliation(s)
- L G Kostrikis
- Aaron Diamond AIDS Research Center, New York University School of Medicine, New York 10016, USA
| | | | | | | | | |
Collapse
|